Mirae Asset Global Investments Co. Ltd. Acquires 69,740 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 33.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 278,234 shares of the medical research company’s stock after purchasing an additional 69,740 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Edwards Lifesciences were worth $26,069,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank Julius Baer & Co. Ltd Zurich grew its stake in Edwards Lifesciences by 98,836.3% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 759,315,387 shares of the medical research company’s stock worth $71,626,220,000 after buying an additional 758,547,908 shares in the last quarter. Moneta Group Investment Advisors LLC increased its stake in Edwards Lifesciences by 104,971.3% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock valued at $1,148,938,000 after acquiring an additional 15,384,593 shares during the last quarter. Norges Bank acquired a new position in Edwards Lifesciences during the fourth quarter valued at approximately $658,390,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in Edwards Lifesciences by 655.9% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company’s stock worth $173,502,000 after purchasing an additional 2,017,801 shares during the last quarter. Finally, Bank of Montreal Can acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $121,091,000. 79.25% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 6,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $65.30, for a total transaction of $391,800.00. Following the completion of the transaction, the vice president now owns 39,503 shares in the company, valued at approximately $2,579,545.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $65.30, for a total transaction of $391,800.00. Following the sale, the vice president now directly owns 39,503 shares of the company’s stock, valued at $2,579,545.90. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Larry L. Wood sold 8,660 shares of Edwards Lifesciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.30, for a total transaction of $565,498.00. Following the completion of the transaction, the insider now owns 213,794 shares of the company’s stock, valued at approximately $13,960,748.20. The disclosure for this sale can be found here. Insiders sold 179,795 shares of company stock valued at $12,724,914 over the last ninety days. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Up 0.4 %

NYSE:EW opened at $67.19 on Tuesday. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $94.87. The firm has a 50-day moving average price of $68.93 and a two-hundred day moving average price of $79.38. The firm has a market cap of $40.75 billion, a price-to-earnings ratio of 28.71, a price-to-earnings-growth ratio of 3.74 and a beta of 1.02. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.45 and a current ratio of 3.28.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.59 earnings per share for the quarter, meeting the consensus estimate of $0.59. The company had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.48 billion. Edwards Lifesciences had a net margin of 24.59% and a return on equity of 24.54%. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.61 earnings per share. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus decreased their price target on shares of Edwards Lifesciences from $87.00 to $70.00 and set a “hold” rating on the stock in a report on Thursday, October 26th. Mizuho cut their target price on shares of Edwards Lifesciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, October 26th. Truist Financial decreased their price target on shares of Edwards Lifesciences from $83.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, October 26th. Citigroup reduced their price objective on shares of Edwards Lifesciences from $94.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, October 26th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $84.29.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.